The intraperitoneal use of crystalline sulfanilamide (powder) in the treatment of generalized peritonitis has aroused considerable interest in the past year. This is evidenced by the recent reports of Dees,1 Thompson, Brabson and Walker2 and Mueller,3 all enthusiastic over the possibilities of this form of treatment. After a thirty-six year survey of the mortality from peritonitis following appendicitis, Nassau, Lorry and Pulaski4 reported a sharp decrease in the mortality and attributed this to the use of sulfanilamide. Ravdin and his associates5 have found a lower mortality in peritonitis associated with appendicitis since the subcutaneous use of crystalline sulfanilamide in physiologic solution of sodium chloride was instituted.
In accord with the ever increasing use of the local application of sulfanilamide in the treatment of peritonitis and other infections, we thought it advisable to determine whether sulfanilamide is as valuable in preventing peritonitis as it is in
LAUFMAN H, WILSON CE. PROPHYLACTIC INTRAPERITONEAL INTRODUCTION OF CRYSTALLINE SULFANILAMIDE: EXPERIMENTAL OBSERVATIONS. Arch Surg. 1942;44(1):55–60. doi:10.1001/archsurg.1942.01210190058007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: